HIV/AIDS vaccination in adolescents would be efficient and practical when vaccine supplies are limited

Vaccine

Volumn 25, Issue 43, 2007, Pages 7502-7509

  Johnson, Leigh F ^a   Bekker, Linda Gail ^a   Dorrington, Rob E ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Adolescent vaccination; HIV AIDS; Mathematical model

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MASS SCREENING; MATHEMATICAL MODEL; PRIORITY JOURNAL; PRODUCTIVITY; SCHOOL; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SOUTH AFRICA; VACCINATION; VACCINE PRODUCTION; WORKER;

ADOLESCENT; ADULT; AFRICA, SOUTHERN; AIDS VACCINES; HUMANS; MODELS, THEORETICAL; VACCINATION;

EID: 34948896517     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.047     Document Type: Article

References (37)

1. Streefland P.H. Introduction of a HIV vaccine in developing countries: social and cultural dimensions. Vaccine 21 (2003) 1304-1309
2. Chang ML, Vitek C, Esparza J. Public health considerations for the use of a first generation HIV vaccine. Report from a WHO-UNAIDS-CDC consultation, Geneva, 20-21 November 2002. AIDS 2003; 17(15):W1-W10.
3. Clements C.J., Abdool-Karim Q., Chang M.L., Nkowane B., and Esparza J. Breaking new ground-are changes in immunization services needed for the introduction of future HIV/AIDS vaccines and other new vaccines targeted at adolescents?. Vaccine 22 (2004) 2822-2826
4. Esparza J., Chang M.L., Widdus R., Madrid Y., Walker N., and Ghys P.D. Estimation of "needs" and "probable uptake" for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study). Vaccine 21 (2003) 2032-2041
5. International AIDS Vaccine Initiative. Assessing the demand for an HIV vaccine; 2005. Policy brief no. 7.
6. Tangcharoensathien V., Phoolcharoen W., Pitayarangsarit S., Kongsin S., Kasemsup V., Tantivess S., et al. The potential demand for an AIDS vaccine in Thailand. Health Policy 57 (2001) 111-139
7. Novaes HMD, Luna EJA, Goldbaum M, Kilsztajn S, Rossbach A, de la Rocha Carvalheiro J. The potential demand for an HIV/AIDS vaccine in Brazil. Washington DC: World Bank; 2002. Policy research working paper 2940.
8. Desmond C, Greener R. The strategic use and potential demand for an HIV vaccine in Southern Africa. Washington DC: World Bank; 2003. Policy research working paper 2977.
9. Barth-Jones DC, Chegulet BK, Longini IM, Marum LH, Ackers ML, Essenmacher L, et al. Modeling the potential impact of a partially effective vaccine in a generalized African HIV-1 epidemic: Evaluating strategies for HIV vaccine use: Emory University, Rollins School of Public Health, Department of Biostatistics; 2003. Technical Report 03-08.
10. Stevens W., and Walker D. Adolescent vaccination in the developing world: time for serious consideration?. Vaccine 22 5-6 (2004) 781-785
11. Amirfar S., Hollenberg J.P., and Abdool Karim S.S. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa. J Acquir Immune Defic Syndr 43 2 (2006) 219-225
12. Jaspan H.B., Lawn S.D., Safrit J.T., and Bekker L.G. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS 20 4 (2006) 483-494
13. Pettifor A.E., Rees H.V., Kleinschmidt I., Steffenson A.E., Macphail C., Hlongwa-Madikizela L., et al. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 19 14 (2005) 1525-1534
14. Johnson LF, Dorrington RE. Assessment of HIV vaccine requirements and effects of HIV vaccination in South Africa: Centre for Actuarial Research; 2006. Available: http://www.commerce.uct.ac.za/Research_units/care.
15. Johnson L.F., and Dorrington R.E. Modelling the demographic impact of HIV/AIDS in South Africa and the likely impact of interventions. Demographic Res 14 (2006) 541-574
16. Halloran M.E., Struchiner C.J., and Longini Jr. I.M. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 146 10 (1997) 789-803
17. Barouch D.H., Santra S., Schmitz J.E., Kuroda M.J., Fu T.M., Wagner W., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290 5491 (2000) 486-492
18. Egan M.A., Charini W.A., Kuroda M.J., Schmitz J.E., Racz P., Tenner-Racz K., et al. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J Virol 74 16 (2000) 7485-7495
19. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 6869 (2002) 331-335
20. O'Brien T.R., Rosenberg P.S., Yellin F., and Goedert J.J. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquir Immune Defic Syndr 18 2 (1998) 155-161
21. Lyles C.M., Dorrucci M., Vlahov D., Pezzotti P., Anagarano G., Sinicco A., et al. Longitudinal human immunodeficiency virus type 1 load in the Italian Seroconversion Study: correlates and temporal trends of virus load. J Infect Dis 180 (1999) 1018-1024
22. Hubert J., Burgard M., Dussaix E., Tamalet C., Deveau C., Le Chenadec J., et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. AIDS 14 (2000) 123-131
23. Scott V.E., Chopra M., Conrad L., and Ntuli A. How equitable is the scaling up of HIV service provision in South Africa?. S Afr Med J 95 2 (2005) 109-113
24. Suraratdecha C., Ainsworth M., Tangcharoensathien V., and Whittington D. The private demand for an AIDS vaccine in Thailand. Health Policy 71 3 (2005) 271-287
25. Jackson D.J., Martin H.L., Bwayo J.J., Nyange P.M., Rakwar J.P., Kashonga F., et al. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya. AIDS 9 11 (1995) 1279-1283
26. Chesney M.A., Chambers D.B., and Kahn J.O. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immun Defic Syndr 16 4 (1997) 266-271
27. Hom D.L., Johnson J.L., Mugyenyi P., Byaruhanga R., Kityo C., Louglin A., et al. HIV-1 risk and vaccine acceptability in the Ugandan military. J Acquir Immune Defic Syndr 15 5 (1997) 375-380
28. Johnson L.F., Dorrington R.E., and Matthews A.P. An investigation into the extent of uncertainty surrounding estimates of the impact of HIV/AIDS in South Africa. S Afr J Sci 103 (2007) 135-140
29. Bekker L.G., and Wood R. Is it time to change our HIV testing policy in health care facilities?. S Afr Med J 96 12 (2006) 1235-1236
30. Voeten H.A., O'Hara H.B., Kusimba J., Otido J.M., Ndinya-Achola J.O., Bwayo J.J., et al. Gender differences in health care-seeking behavior for sexually transmitted diseases: a population-based study in Nairobi, Kenya. Sex Transm Dis 31 5 (2004) 265-272
31. Nuwaha F. Determinants of choosing public or private health care among patients with sexually transmitted infections in Uganda. Sex Transm Dis 33 7 (2006) 422-427
32. Schneider H., Blaauw D., Dartnall E., Coetzee D.J., and Ballard R.C. STD care in the South African private health sector. S Afr Med J 91 (2001) 151-156
33. Statistics South Africa. General household survey, July 2004. Pretoria; 2005.
34. Bekker L.G., Jaspan H., McIntyre J., Wood R., and Gray G. Adolescents and HIV vaccine trials: what are the clinical trial site issues?. J Int Assoc Physicians AIDS Care 4 4 (2005) 93-97
35. Barth-Jones D.C., Cheng H., Kang L.Y., Kenya P.R., Odera D., Mosqueira N.R., et al. Cost effectiveness and delivery study for future HIV vaccines. AIDS 19 13 (2005) w1-w6
36. Owens D.K., Edwards D.M., Cavallaro J.F., and Shachter R.D. The cost effectiveness of partially effective HIV vaccines. In: Brandeau M.L., Sainfort F., and Pierskalla W.P. (Eds). Operations research and health care: a handbook of methods and applications. (2004), Kluwer Academic Publishers, Boston
37. Stover J, Garnett G, Seitz S, Forsythe S. The epidemiological impact of an HIV/AIDS vaccine in developing countries. Washington DC: World Bank; 2002. Policy research working paper 2811.